about
Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversionsUse of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012).Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIVBrief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.Clinical utility of maraviroc.Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).Executive summary of the consensus document on the management of renal disease in HIV-infected patients.Consensus document on the management of renal disease in HIV-infected patients.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER StudyEmpirical monotherapy with meropenem or combination therapy: the microbiological point of view.Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients.Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients.Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.Biological markers of fertility (inhibin-B) in HIV-infected men: influence of HIV infection and antiretroviral therapy.[Influence of sample conservation on quantification of Hepatitis C Virus RNA].[Infectious diseases in the adult population admitted to a general hospital].[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis.Measles in adults during an outbreak in Spain: hospitalization associated with gastrointestinal and liver involvement.Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.[Mechanism of action and pharmacokinetics of rilpivirine].[Reproducibility of a method to quantify vaginal human immunodeficiency virus viral load].Polyostotic osteitis in secondary syphilis in an HIV-infected patient.Angiolipomas, a rare manifestation of HIV-associated lipodystrophy.Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide.Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients.[Association between inflammatory markers and microbial translocation in patients with human immunodeficiency virus infection taking antiretroviral treatment].Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders].[Utility of 2 biochemical models predictive of liver fibrosis grade in prison inmates with hepatitis C].Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.[Hypogonadism, erectile dysfunction and endothelial dysfunction among HIV-infected men].
P50
Q28542942-DAF122ED-6BD4-42A1-9602-12AC4E275B11Q30886765-8D2470EE-F153-403C-A3AC-18F5A738C26FQ33615509-7E617A99-D8CB-4CCA-A42B-36D2C2102537Q36282716-8E053F7A-101A-4E61-B936-F069976BDCD5Q37877242-A11C26D3-6866-4ADA-A491-44949261DA6FQ38225483-C3DB9D29-1B40-43E2-BE8C-80593008BCD3Q38270322-E3E273CF-A311-4731-BAC9-B77CF797394FQ38281715-F3EB8A8D-45B1-4662-A317-F6F5569B31D8Q38505953-8C825341-F62B-4A1B-9286-8D742FD81452Q39097955-421B06A9-0BA9-481E-A710-0A2B062C7631Q39510473-35CF4223-80CE-47E9-8D18-A2702253F6F6Q39550328-1B76B7C1-FC3B-414D-853D-18F25BF40880Q40364181-CA058C6B-3A0A-4AAD-85ED-CFC79B897541Q40723867-230E5D51-3BCF-478C-8CA2-1F2DD130F279Q40755766-C459963D-07E3-4E0B-8BF4-4DCFFF0F8060Q40863813-347759E0-DE35-4275-9DC0-1A687E12895CQ40928376-BACEBAFC-0005-47D3-89A6-11FB248A23ADQ41581515-D201007E-B6F4-49F8-BB91-AA44850AE4D5Q41706281-57AC3C25-EC11-478A-8177-BC2C70A46CADQ41920983-EBACE5A7-A550-47FF-B741-846C9B898515Q42209052-65BC0B65-5D41-4193-AE8D-2253953A67AEQ42243459-F4CD9DDA-CC5C-40F6-881C-4BCB4FCC5B4EQ42243725-7F663B5A-9903-424C-9C04-1ABB9E1C1F2BQ42640549-FA3B1EA4-8287-4091-83FF-DA19E3920161Q42686260-D33C8847-0543-4EBF-811E-E39CBF16D9BDQ42977009-A43C0952-BB87-49BB-B5A9-10EEA15E1382Q43034985-01541754-B717-4141-B9F1-BB2B471447CDQ43714075-2513D833-B478-4A63-BAF1-C8F1531E1044Q43749924-08A6A95E-C905-43BD-A11B-7EFEA8E61B5AQ44008652-FADBBDEF-B847-483B-B63C-9F8706760F6DQ44237720-A31ADF06-EB09-4AD7-8223-B31CD17C1576Q44461030-0800C98E-F35B-44C7-A1D0-4D20583EFB73Q44920003-0B33C181-C8DF-4460-BB8C-B4344FF1E0B5Q45024589-A2408BA2-5F28-494B-B03B-E0009417C4EBQ45329093-54CF10DC-BDCE-4010-A0C8-6AEE550324AAQ45404496-1CB18737-6035-4276-A8E0-290D0DB58585Q45927699-4A3DF170-8D25-4F3A-BE92-DC55E3033B5BQ45992019-B6A38B85-8C7D-4F8E-AA72-FB3BCA9BBE27Q46059384-673BB34C-E0B7-4611-9D72-F195CD714CACQ46099111-6BF20B55-73B0-49D9-906A-E878BEEE4E18
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joaquín Portilla
@ast
Joaquín Portilla
@en
Joaquín Portilla
@es
Joaquín Portilla
@nl
type
label
Joaquín Portilla
@ast
Joaquín Portilla
@en
Joaquín Portilla
@es
Joaquín Portilla
@nl
prefLabel
Joaquín Portilla
@ast
Joaquín Portilla
@en
Joaquín Portilla
@es
Joaquín Portilla
@nl
P106
P21
P31
P496
0000-0002-3676-9511